Trial · NCT06982859
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
NCT06982859, Phase 1, Active not recruiting, Eli Lilly and Company
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus. Trials, record NCT06982859. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06982859
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
- NCT number
- NCT06982859
- Status
- Active not recruiting
- Phases
- Phase 1
- Enrollment
- 95 participants, estimated
- Lead sponsor
- Eli Lilly and Company
- Conditions
- Diabetes Mellitus, Insulin Sensitivity
- Interventions
- Retatrutide, Semaglutide, Placebo
- First posted
- 2025-05-21
- Last updated
- 2026-10-06
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Total Clamp Disposition Index (cDI) for Comparison of Retatrutide With Placebo | Baseline, Week 28 | Change from baseline in total cDI for comparison of retatrutide with placebo |
| Secondary | Change from Baseline in cDI for Comparison Between Retatrutide and Semaglutide | Baseline, Week 28 | Change from baseline in total cDI for comparison between retatrutide and semaglutide |
| Secondary | Change from Baseline in Hyperinsulinemic Euglycemic Clamp M-value | Baseline, Week 28 | Change from baseline in hyperinsulinemic euglycemic clamp M-value |
| Secondary | Change from Baseline in First Phase Incremental Insulin Secretion Rate (ISR) | Baseline, Week 28 | Change from baseline in first phase ISR. |
| Secondary | Change from Baseline in Second Phase Total ISR | Baseline, Week 28 | Change from baseline in second phase total ISR |
| Secondary | Change from Baseline in Total ISR | Baseline, Week 28 | Change from baseline in total ISR |
| Secondary | Change from Baseline in Insulin Response to Arginine [Incremental Insulin Area Under the Curve (AUC) arginine, 0-10minutes] | Baseline, Week 28 | Change from baseline in insulin response to arginine \[Incremental Insulin AUC arginine, 0-10minutes\]. |
| Secondary | Change from Baseline in Insulin Response to Arginine (Incremental Insulin AUC arginine, 0-30minutes) | Baseline, Week 28 | Change from baseline in insulin response to arginine (Incremental Insulin AUC arginine, 0-30minutes). |
| Secondary | Change from Baseline in Beta-cell (β-cell) Glucose Sensitivity (GS) | Baseline, Week 28 | Change from baseline in β-cell GS. |
| Secondary | Change from Baseline in β-cell Glucose Sensitivity (GS) from Standardized Mixed-Meal Tolerance Test (sMMTT) | Baseline, Week 28 | Change from baseline in β-cell GS from sMMTT. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06982859
GET https://conductscience.org/api/trials/v1/NCT06982859/registered